Opendata, web and dolomites

INFarm SIGNED

A unique, interferon-based veterinary therapy to minimize antimicrobial overuse in cattle and tackle the societal global problem of antimicrobial resistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 INFarm project word cloud

Explore the words cloud of the INFarm project. It provides you a very rough idea of what is the project "INFarm" about.

renounce    pharmaceutical    prevent    overuse    reduce    viral    completing    largely    enormous    upfront    resistance    commercialization    payments    antimicrobials    sustainable    accounting    77    perform    livestock    bacterial    minimize    return    milestone    business    market    global    strengthen    farmpharma    receive    risk    amr    mission    commercialize    appropriate    abundant    health    clinical    mis    affordable    threat    lack    121    respectively    alternative    94    commercial    interferon    solutions    licensing    drugs    strategy    anti    alternatives    immune    chance    chain    royalty    maximize    keep    ip    total    consolidated    give    antimicrobial    company    thereby    billion    deal    infrastructure    public    income    markets    feasibility    infections    optimal    solution    humans    million    animals    infective    addressable    demand    safe    volume    hindering    pressure    clear    treat    therapy    healthy    plan    realizing    interferox    stimulating    farmers    output    putting    2050    deaths    cattle    validation   

Project "INFarm" data sheet

The following table provides information about the project.

Coordinator
FARMPHARMA AB 

Organization address
address: VIRDINGS ALLE 32B
city: UPPSALA
postcode: 754 50
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.farmpharma.se/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FARMPHARMA AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The rise of antimicrobial resistance (AMR) is a major threat to global public health as it will cause 10 million deaths per year by 2050. The rise in AMR is largely driven by the abundant mis- and overuse of antimicrobial drugs in humans and animals. As such, there is a strong demand to reduce the use of antimicrobials in animals, putting cattle farmers under enormous pressure to change their current way of working. However, the lack of appropriate alternatives is hindering them to renounce from (over)using antimicrobials as their production output and income are at risk.

At FarmPharma, we are on the mission to provide effective, safe and affordable solutions to keep livestock animals healthy and well. To do so, we are developing InterferOx, an interferon-based, immune-stimulating, anti-infective therapy for cattle with the unique ability to treat AND prevent viral AND bacterial infections. InterferOx can thus minimize the use of antimicrobials in cattle by providing farmers an effective and sustainable alternative, thereby providing a solution for the rise in AMR.

The global market volume is 1.5 billion cattle, with our total addressable markets of Europe and US accounting for 121 and 94 million, respectively. With InterferOx, we respond to the trends and needs of our €1.7 billion target market: the cattle antimicrobials market. We aim to commercialize InterferOx via a licensing deal with a pharmaceutical company after completing clinical validation. In return, we will receive upfront, milestone and royalty payments with an estimated value of €77.8 million within the next 7 years.

To maximize our chance of realizing this promising future, we will perform a feasibility study, focusing on market analysis, commercialization strategy, IP strategy and value chain, to deliver a consolidated business plan. This will give us a clear understanding of the commercial potential of InterferOx, strengthen our current infrastructure, and define our optimal business strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INFARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More